載入...
Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma
Fewer than 50% of patients with high-risk neuroblastoma survive five years after diagnosis with current treatment protocols. Molecular targeted therapies are expected to improve survival. Although MDM2 has been validated as a promising target in preclinical models, no MDM2 inhibitors have yet entere...
Na minha lista:
| 發表在: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Impact Journals LLC
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5788641/ https://ncbi.nlm.nih.gov/pubmed/29416773 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.23409 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|